ReviewAmerican journal of clinical dermatology2026
Dissecting Cellulitis of the Scalp: Current Insights and Therapeutic Advances.
Review in American journal of clinical dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic and Psychiatric Comorbidities in Dissecting Cellulitis of the Scalp: A Retrospective Cohort Study and Scoping Review.Dermatology and therapy · 2026Article
- Diagnostic Challenges and Treatment Strategies in Neutrophilic Cicatricial Alopecias: A Narrative Review from Conventional Therapies to New Therapeutic Targets.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dissecting cellulitis of the scalp is a rare, primary neutrophilic cicatricial alopecia that manifests with painful nodules, abscesses, and interconnected sinus tracts. It predominantly affects young adult men and frequently coexists with other follicular occlusion disorders, including hidradenitis suppurativa and acne conglobata. Clinical evaluation and trichoscopy are key elements of the diagnostic work-up, allowing detection of both early non-scarring inflammatory changes and features of chronic fibrotic disease. Although a wide array of therapeutic options has been explored, which range from oral antibiotics and retinoids to biologic agents, evidence-based guidelines remain lacking, and disease recurrence is common upon treatment cessation. Recent therapeutic advances have identified tumor necrosis factor-α, interleukin-17, and interleukin-23 inhibitors as promising options in recalcitrant cases. Adjunctive modalities such as laser-based therapies, surgical excision, and photodynamic protocols further expand the therapeutic paradigm, particularly for advanced disease. Increasing clinical and pathogenic evidence supports shared inflammatory pathways between dissecting cellulitis of the scalp and hidradenitis suppurativa, suggesting that these entities may represent anatomical variants within the same disease spectrum, driven by follicular occlusion and dysregulated immune responses. This evolving view harbors important implications for disease classification and management. The aim of this review is to provide an updated overview of the latest evidence on dissecting cellulitis of the scalp, encompassing its epidemiology, pathogenesis, clinical presentation, diagnostic algorithm, and therapeutic strategies. Additionally, we critically evaluate the conceptual framework for viewing dissecting cellulitis of the scalp and hidradenitis suppurativa as phenotypic variants of a unified inflammatory disorder and assess the current unmet need and future perspectives in translational research and disease management.
Indexed as
Identifiers
41945009What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.